These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38253262)

  • 1. Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics.
    Arslan B; Zetterberg H; Ashton NJ
    Clin Chem Lab Med; 2024 May; 62(6):1063-1069. PubMed ID: 38253262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
    Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
    Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
    Wojdała AL; Bellomo G; Gaetani L; Toja A; Chipi E; Shan D; Chiasserini D; Parnetti L
    Neurobiol Dis; 2023 Dec; 189():106356. PubMed ID: 37977432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dynamics of plasma biomarkers across the Alzheimer's continuum.
    Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
    Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
    Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
    JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
    Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
    Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
    Brickman AM; Manly JJ; Honig LS; Sanchez D; Reyes-Dumeyer D; Lantigua RA; Lao PJ; Stern Y; Vonsattel JP; Teich AF; Airey DC; Proctor NK; Dage JL; Mayeux R
    Alzheimers Dement; 2021 Aug; 17(8):1353-1364. PubMed ID: 33580742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay.
    Dyer AH; Dolphin H; O'Connor A; Morrison L; Sedgwick G; Young C; Killeen E; Gallagher C; McFeely A; Connolly E; Davey N; Claffey P; Doyle P; Lyons S; Gaffney C; Ennis R; McHale C; Joseph J; Knight G; Kelly E; O'Farrelly C; Fallon A; O'Dowd S; Bourke NM; Kennelly SP
    Alzheimers Res Ther; 2024 Aug; 16(1):186. PubMed ID: 39160628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study.
    Chen Y; Wang Y; Tao Q; Lu P; Meng F; Zhuang L; Qiao S; Zhang Y; Luo B; Liu Y; Peng G
    Clin Chim Acta; 2024 May; 558():118784. PubMed ID: 38588788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
    Ashton NJ; Puig-Pijoan A; Milà-Alomà M; Fernández-Lebrero A; García-Escobar G; González-Ortiz F; Kac PR; Brum WS; Benedet AL; Lantero-Rodriguez J; Day TA; Vanbrabant J; Stoops E; Vanmechelen E; Triana-Baltzer G; Moughadam S; Kolb H; Ortiz-Romero P; Karikari TK; Minguillon C; Hernández Sánchez JJ; Navalpotro-Gómez I; Grau-Rivera O; María Manero R; Puente-Periz V; de la Torre R; Roquer J; Dage JL; Zetterberg H; Blennow K; Suárez-Calvet M
    Alzheimers Dement; 2023 May; 19(5):1913-1924. PubMed ID: 36370462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in blood biomarkers for Alzheimer disease (AD): A review.
    Assfaw AD; Schindler SE; Morris JC
    Kaohsiung J Med Sci; 2024 Aug; 40(8):692-698. PubMed ID: 38888066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models.
    Cullen NC; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Bittner T; Suridjan I; Jethwa A; Kollmorgen G; Brum WS; Zetterberg H; Blennow K; Stomrud E; Hansson O
    Alzheimers Dement; 2023 Mar; 19(3):797-806. PubMed ID: 35699240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.
    Therriault J; Servaes S; Tissot C; Rahmouni N; Ashton NJ; Benedet AL; Karikari TK; Macedo AC; Lussier FZ; Stevenson J; Wang YT; Fernandez-Arias J; Stevenson A; Socualaya KQ; Haeger A; Nazneen T; Aumont É; Hosseini A; Rej S; Vitali P; Triana-Baltzer G; Kolb HC; Soucy JP; Pascoal TA; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
    Alzheimers Dement; 2023 Nov; 19(11):4967-4977. PubMed ID: 37078495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease].
    Blennow K; Hansson O
    Lakartidningen; 2024 May; 121():. PubMed ID: 38818759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between PET and blood plasma biomarkers in corticobasal syndrome.
    Singh NA; Alnobani A; Graff-Radford J; Machulda MM; Mielke MM; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Kanekiyo T; Josephs KA; Whitwell JL
    Alzheimers Dement; 2024 Jul; 20(7):4765-4774. PubMed ID: 38885334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.